- Home
- PVL vs SYRS Comparison
PVL vs SYRS Comparison
Compare PVL & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- SYRS
- Stock Information
- Founded
- PVL 2011
- SYRS 2011
- Country
- PVL United States
- SYRS United States
- Employees
- PVL N/A
- SYRS N/A
- Industry
- PVL Oil & Gas Production
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- SYRS Health Care
- Exchange
- PVL Nasdaq
- SYRS Nasdaq
- Market Cap
- PVL 51.1M
- SYRS 7.1M
- IPO Year
- PVL N/A
- SYRS 2016
- Fundamental
- Price
- PVL $1.38
- SYRS $0.22
- Analyst Decision
- PVL
- SYRS Hold
- Analyst Count
- PVL 0
- SYRS 5
- Target Price
- PVL N/A
- SYRS $3.00
- AVG Volume (30 Days)
- PVL 75.7K
- SYRS 2.7M
- Earning Date
- PVL 01-01-0001
- SYRS 10-31-2024
- Dividend Yield
- PVL 6.23%
- SYRS N/A
- EPS Growth
- PVL N/A
- SYRS N/A
- EPS
- PVL 0.20
- SYRS N/A
- Revenue
- PVL $3,142,081.00
- SYRS $386,000.00
- Revenue This Year
- PVL N/A
- SYRS N/A
- Revenue Next Year
- PVL N/A
- SYRS $1,011.11
- P/E Ratio
- PVL $6.81
- SYRS N/A
- Revenue Growth
- PVL N/A
- SYRS N/A
- 52 Week Low
- PVL $1.03
- SYRS $0.18
- 52 Week High
- PVL $1.96
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- PVL 29.68
- SYRS 29.17
- Support Level
- PVL $1.31
- SYRS $0.19
- Resistance Level
- PVL $1.54
- SYRS $0.21
- Average True Range (ATR)
- PVL 0.05
- SYRS 0.02
- MACD
- PVL -0.01
- SYRS 0.07
- Stochastic Oscillator
- PVL 25.93
- SYRS 20.53
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.